DUBLIN--(BUSINESS WIRE)--The "Prostate Cancer Diagnostics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
Amid the COVID-19 crisis, the global market for Prostate Cancer Diagnostics estimated at US$3.1 Billion in the year 2020, is projected to reach a revised size of US$6.8 Billion by 2027, growing at a CAGR of 11.9% over the period 2020-2027.
Preliminary, one of the segments analyzed in the report, is projected to record 11.3% CAGR and reach US$5.1 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Confirmatory segment is readjusted to a revised 13.8% CAGR for the next 7-year period.
The U.S. Market is Estimated at $842.1 Million, While China is Forecast to Grow at 15.5% CAGR
The Prostate Cancer Diagnostics market in the U.S. is estimated at US$842.1 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.5 Billion by the year 2027 trailing a CAGR of 15.5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.4% and 10.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 9.3% CAGR.
Select Competitors (Total 34 Featured):
- 3D Signatures
- Abbott
- Beckman Coulter, Inc.
- Biomerieux Sa
- Diasorin S.P.A.
- F. Hoffman La Roche Ltd.
- Genomic Health
- Mdxhealth
- Myriad Genetic, Inc.
- Opko Health, Inc.
- Siemens Healthcare Gmbh
Key Topics Covered:
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
IV. COMPETITION
- Total Companies Profiled: 34
For more information about this report visit https://www.researchandmarkets.com/r/n0hwqt
